|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kurman RJ and Shih IeM: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park SM, Shell S, Radjabi AR, Schickel R,
Feig C, Boyerinas B, Dinulescu DM, Lengyel E and Peter ME: Let-7
prevents early cancer progression by suppressing expression of the
embryonic gene HMGA2. Cell Cycle. 6:2585–2590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Welsh JB, Zarrinkar PP, Sapinoso LM, Kern
SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA and Hampton GM:
Analysis of gene expression profiles in normal and neoplastic
ovarian tissue samples identifies candidate molecular markers of
epithelial ovarian cancer. Proc Natl Acad Sci USA. 98:1176–1181.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wei JJ, Wu J, Luan C, Yeldandi A, Lee P,
Keh P and Liu J: HMGA2: A potential biomarker complement to P53 for
detection of early-stage high-grade papillary serous carcinoma in
fallopian tubes. Am J Surg Pathol. 34:18–26. 2010. View Article : Google Scholar
|
|
7
|
Wu J, Liu Z, Shao C, Gong Y, Hernando E,
Lee P, Narita M, Muller W, Liu J and Wei JJ: HMGA2
overexpression-induced ovarian surface epithelial transformation is
mediated through regulation of EMT genes. Cancer Res. 71:349–359.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malek A, Bakhidze E, Noske A, Sers C,
Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising
target for ovarian cancer silencing therapy. Int J Cancer.
123:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu J and Wei JJ: HMGA2 and high-grade
serous ovarian carcinoma. J Mol Med Berl. 91:1155–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morishita A, Zaidi MR, Mitoro A,
Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K:
HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zha L, Zhang J, Tang W, Zhang N, He M, Guo
Y and Wang Z: HMGA2 elicits EMT by activating the Wnt/β-catenin
pathway in gastric cancer. Dig Dis Sci. 58:724–733. 2013.
View Article : Google Scholar
|
|
12
|
Serlachius M, Alitalo R, Olsen HS and
Andersson LC: Expression of stanniocalcin-1 in megakaryocytes and
platelets. Br J Haematol. 119:359–363. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang AC and Reddel RR: Identification of
a second stanniocalcin cDNA in mouse and human: Stanniocalcin 2.
Mol Cell Endocrinol. 141:95–99. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu G, Yang G, Chang B, Mercado-Uribe I,
Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and
ovarian tumorigenesis. J Natl Cancer Inst. 102:812–827. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ieta K, Tanaka F, Yokobori T, Kita Y,
Haraguchi N, Mimori K, Kato H, Asao T, Inoue H, Kuwano H, et al:
Clinicopathological significance of stanniocalcin 2 gene expression
in colorectal cancer. Int J Cancer. 125:926–931. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Girgis AH, Iakovlev VV, Beheshti B, Bayani
J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H, et
al: Multilevel whole-genome analysis reveals candidate biomarkers
in clear cell renal cell carcinoma. Cancer Res. 72:5273–5284. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan Y, Yang ZL, Zou Q, Li JH, Li DQ,
Liang LF, Zeng GX and Chen SL: Comparative study of
clinicopathological significance, BIRC7, and STC2 expression
between squamous cell/adenosquamous carcinomas and adenocarcinoma
of gallbladder. Neoplasma. 60:698–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Buckanovich RJ, Sasaroli D,
O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos
R, Liotta LA, Gimotty PA and Coukos G: Tumor vascular proteins as
biomarkers in ovarian cancer. J Clin Oncol. 25:852–861. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Law AY and Wong CK: Stanniocalcin-2 is a
HIF-1 target gene that promotes cell proliferation in hypoxia. Exp
Cell Res. 316:466–476. 2010. View Article : Google Scholar
|
|
20
|
McMillen BD, Aponte MM, Liu Z, Helenowski
IB, Scholtens DM, Buttin BM and Wei JJ: Expression analysis of
MIR182 and its associated target genes in advanced ovarian
carcinoma. Mod Pathol. 25:1644–1653. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui T and Leng F: Specific recognition of
AT-rich DNA sequences by the mammalian high mobility group protein
AT-hook 2: A SELEX study. Biochemistry. 46:13059–13066. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bouras T, Southey MC, Chang AC, Reddel RR,
Willhite D, Glynne R, Henderson MA, Armes JE and Venter DJ:
Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the
estrogen receptor in human breast cancer. Cancer Res. 62:1289–1295.
2002.PubMed/NCBI
|
|
23
|
Law AY and Wong CK: Stanniocalcin-2
promotes epithelial-mesenchymal transition and invasiveness in
hypoxic human ovarian cancer cells. Exp Cell Res. 316:3425–3434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yokobori T, Mimori K, Ishii H, Iwatsuki M,
Tanaka F, Kamohara Y, Ieta K, Kita Y, Doki Y, Kuwano H, et al:
Clinical significance of stanniocalcin 2 as a prognostic marker in
gastric cancer. Ann Surg Oncol. 17:2601–2607. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang YY, Li L, Zhao ZS and Wang HJ:
Clinical utility of measuring expression levels of KAP1, TIMP1 and
STC2 in peripheral blood of patients with gastric cancer. World J
Surg Oncol. 11:812013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Volland S, Kugler W, Schweigerer L,
Wilting J and Becker J: Stanniocalcin 2 promotes invasion and is
associated with metastatic stages in neuroblastoma. Int J Cancer.
125:2049–2057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang H, Wu K, Sun Y, Li Y, Wu M, Qiao Q,
Wei Y, Han ZG and Cai B: STC2 is upregulated in hepatocellular
carcinoma and promotes cell proliferation and migration in vitro.
BMB Rep. 45:629–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dondeti VR, Wubbenhorst B, Lal P, Gordan
JD, D'Andrea K, Attiyeh EF, Simon MC and Nathanson KL: Integrative
genomic analyses of sporadic clear cell renal cell carcinoma define
disease subtypes and potential new therapeutic targets. Cancer Res.
72:112–121. 2012. View Article : Google Scholar :
|
